Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antiplatelet treatment in unstable angina: aspirin, clopidogrel, glycoprotein IIb/IIIa antagonist, or all three?

22 in total

Review 1. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists in the medical management of unstable angina.

Authors: M S McDonagh; L M Bachmann; S Golder; J Kleijnen; G ter Riet
Journal: Health Technol Assess Date: 2000 Impact factor: 4.014

Review 2. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition.

Authors: D P Chew; D J Moliterno
Journal: J Am Coll Cardiol Date: 2000-12 Impact factor: 24.094

3. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial.

Authors: M L Simoons
Journal: Lancet Date: 2001-06-16 Impact factor: 79.321

4. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.

Authors: E J Topol; D J Moliterno; H C Herrmann; E R Powers; C L Grines; D J Cohen; E A Cohen; M Bertrand; F J Neumann; G W Stone; P M DiBattiste; L Demopoulos
Journal: N Engl J Med Date: 2001-06-21 Impact factor: 91.245

5. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Authors: C P Cannon; W S Weintraub; L A Demopoulos; R Vicari; M J Frey; N Lakkis; F J Neumann; D H Robertson; P T DeLucca; P M DiBattiste; C M Gibson; E Braunwald
Journal: N Engl J Med Date: 2001-06-21 Impact factor: 91.245

6. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy.

Authors: L K Newby; E M Ohman; R H Christenson; D J Moliterno; R A Harrington; H D White; P W Armstrong; F Van De Werf; M Pfisterer; V Hasselblad; R M Califf; E J Topol
Journal: Circulation Date: 2001-06-19 Impact factor: 29.690

7. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

Authors:
Journal: N Engl J Med Date: 1998-05-21 Impact factor: 91.245

8. Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK)

Authors: J Collinson; M D Flather; K A Fox; I Findlay; E Rodrigues; P Dooley; P Ludman; J Adgey; T J Bowker; R Mattu
Journal: Eur Heart J Date: 2000-09 Impact factor: 29.983

Review 9. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.

Authors: E Boersma; K M Akkerhuis; P Théroux; R M Califf; E J Topol; M L Simoons
Journal: Circulation Date: 1999-11-16 Impact factor: 29.690

10. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network.

Authors:
Journal: Circulation Date: 1998-06-23 Impact factor: 29.690

1 in total

1. Antithrombotic effect of Z4A5 on coronary thrombosis in a canine model of acute unstable angina.

Authors: Bo-Bin Jing; Ying-Xue Li; Hui Zhang; Shu-Ting Ren; Mei Wang; Yi-Ping Li; Xin-Liang Shen; Yi-Li Wang; Wei-Jin Zang; Bing Wang
Journal: Br J Pharmacol Date: 2013-06 Impact factor: 8.739

1 in total